Alkermes and 5461 Are Back In Busineas

[anonymous]

U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461. FDA's target action date for the ALKS 5461 NDA is January 31, 2019.

 

[anonymous]

U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461. FDA's target action date for the ALKS 5461 NDA is January 31, 2019.

This drug does not have a shot. The FDA has agreed to take Alkermes' money to review this dog and will issue the bad news next January. Anyone who takes a chance on this one better have plans of where you are going come January because Alkermes will drop you like a hot potato. This company is propping up their stock price with anything they can because every single quarter they lose more money. Their products are all 3rd tier remakes of generic drugs and Aristada has not even broken 100 million in year yet. Unbeleivable

 

[anonymous]

This drug does not have a shot. The FDA has agreed to take Alkermes' money to review this dog and will issue the bad news next January. Anyone who takes a chance on this one better have plans of where you are going come January because Alkermes will drop you like a hot potato. This company is propping up their stock price with anything they can because every single quarter they lose more money. Their products are all 3rd tier remakes of generic drugs and Aristada has not even broken 100 million in year yet. Unbeleivable

But Latuda will lose its patent next year. We are doomed if we stay here!

 

[anonymous]

This drug does not have a shot. The FDA has agreed to take Alkermes' money to review this dog and will issue the bad news next January. Anyone who takes a chance on this one better have plans of where you are going come January because Alkermes will drop you like a hot potato. This company is propping up their stock price with anything they can because every single quarter they lose more money. Their products are all 3rd tier remakes of generic drugs and Aristada has not even broken 100 million in year yet. Unbeleivable

I for one will be interviewing to sell 5461. I can’t wait to leave this place. The negative crap and waste of time conference calls that Coktoasten makes us sit thru is too much for a sane person to take. Either Coktoasten goes or I and many more will be leaving.

 

[anonymous]

I for one will be interviewing to sell 5461. I can’t wait to leave this place. The negative crap and waste of time conference calls that Coktoasten makes us sit thru is too much for a sane person to take. Either Coktoasten goes or I and many more will be leaving.

We don’t want you here! Please leave!

Timmy

 

[anonymous]

But Latuda will lose its patent next year. We are doomed if we stay here!

You're better staying here where you have a chance at selling two things than going to Alks hoping for a miracle. Good luck either way.

 

[anonymous]

If I could go to alkremes why would I not? When we lose Latuda next year we will be a smaller company looking at total sales less than alkermes. Yet, we will have a sales force that is roughly 3.5 times larger than Alkermes. You do the math Sparky.

Let's see. Remove Latuda and all of our other products have a combined $539 million in sales. Looking at the Alkermes annual report they do $368 million a year in Vivitril sales (growth rate of 62% YoY), $173 million in Aristada sales (growth rate of 49%YoY) and a little over $600 million a year through royalties on their delivery systems used in Resperdel Consta and Invega Sustaina. They are over $1.1 billion in gross sales and growing while we will be about half than after we lose Latuda patent in 2019.

Add to that all the Sunovion people who I know that went there love it.

So why would I not take a job with them if they offered?

 

[anonymous]

maybe stay because they wont get it approved? those other revenue dollars already have a rep supporting them.